Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma

Inclusion Criteria: * HIV-1 seropositive at or before the time of lymphoma diagnosis * Karnofsky performance status \>= 70% * Biopsy proven NHL, including plasmablastic lymphoma and primary effusion lymphoma but not T-cell lymphoma; tissue histology will be reviewed at City of Hope (COH); patients who have been in remission for \> 1 year post Hodgkin's lymphoma chemotherapy are also considered eligible * \>= 28 days from completion of frontline chemotherapy for NHL * If remission status \< 1 year for NHL, complete remission documented by computed tomography (CT) or positron emission tomography (PET)-CT scan within 3 months of study entry * No diagnosed psychosocial conditions that would hinder study compliance and follow-up * Pretreatment serum glutamic oxaloacetic transaminase (SGOT), serum glutamate pyruvate transaminase (SGPT) =\< 2.5 x institutional upper limit of normal (ULN) * Pretreatment serum bilirubin =\< 2.5 x institutional ULN or - Total bilirubin \< 4.5 mg/dl with direct fraction =\< 0.3 mg/dl in patients for whom these abnormalities are felt to be due to protease inhibitor therapy * Serum creatinine \< 2 x the institutional ULN * Absence of clinically significant cardiomyopathy, congestive heart failure * Cardiac ejection fraction has to be \>= 50% * Spirometry diffusion capacity (diffusion capacity of the lung for carbon monoxide \[DLCO\]) \>= 50% * If the subject is female and of child-bearing potential, subject must have negative serum or urine pregnancy tes…